benufutamab (GEN1029) / Genmab  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
benufutamab (GEN1029) / Genmab
NCT03576131 / 2017-001394-16: GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors

Terminated
1/2
48
Europe, US
GEN1029 (HexaBody®-DR5/DR5)
Genmab
Colorectal Cancer, Non-small Cell Lung Cancer, Triple Negative Breast Cancer, Renal Cell Carcinoma, Gastric Cancer, Pancreatic Cancer, Urothelial Cancer
10/21
10/21

Download Options